J. Barrett

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

A. Pollard, P. Aley, M. Voysey, 2022, eBioMedicine.

Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine

D. Lauffenburger, D. Douek, G. Alter, 2022, medRxiv.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria.

C. Janse, A. Villegas-Méndez, K. Couper, 2020, Parasite immunology.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics

A. Lawrie, W. Nahrendorf, S. Draper, 2022, Frontiers in Immunology.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice

A. Liston, M. Linterman, D. Bailey, 2020, bioRxiv.

Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding

L. Picker, A. McMichael, P. Borrow, 2018, Nature Communications.

Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors

B. Haynes, P. Borrow, Yue Chen, 2021, Cell reports. Medicine.

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

A. Lawrie, M. Higgins, A. Tahiri-Alaoui, 2018, npj Vaccines.

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

A. Lawrie, M. Higgins, A. Tahiri-Alaoui, 2018, npj Vaccines.

Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly

J. Rayner, T. Otto, A. Blagborough, 2021, JCI insight.

Controlled human malaria infection with PvW1: a new clone of Plasmodium vivax with high quality genome assembly

J. Rayner, T. Otto, A. Blagborough, 2021, medRxiv.

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

G. Alter, M. White, S. Faust, 2021, Med.

Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation

M. Howarth, T. Bowden, P. Rijal, 2020, Angewandte Chemie.

Adaptive T cells regulate disease tolerance in human malaria

A. Ivens, W. Nahrendorf, G. Napolitani, 2021, medRxiv.

Mapping T cell activation and differentiation at single cell resolution in naive hosts infected with Plasmodium vivax

J. Rayner, A. Ivens, G. Napolitani, 2022 .

Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding

L. Picker, A. McMichael, P. Borrow, 2018, Nature Communications.

Parasite species regulates T cell activation in human malaria

J. Rayner, A. Ivens, G. Napolitani, 2021, medRxiv.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran, Andreas C. Themistocleous, M. Wand, 2021, Nature Medicine.

Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

A. Olotu, C. Chitnis, S. Draper, 2023, medRxiv.

Impact of a blood-stage vaccine on Plasmodium vivax malaria

R. Moon, C. Huon, C. Chitnis, 2022, medRxiv.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, P. Klenerman, T. Wrin, 2021, Nature Medicine.

Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies

M. Fay, A. Olotu, S. Draper, 2023, Malaria Journal.

Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies

M. Diakité, S. Draper, C. Long, 2021, Cell reports. Medicine.

Superior antibody immunogenicity of a RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults

A. Olotu, A. Lawrie, S. Draper, 2023, medRxiv.

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

R. Moon, C. Huon, C. Chitnis, 2023, Science Translational Medicine.

PvDBPII-Matrix M elicits polyfunctional antibodies that limit parasite growth in a challenge trial

F. Agou, C. Huon, C. Chitnis, 2023, medRxiv.

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.

A. Olotu, Saumu Ahmed, A. Ali, 2023, Med.

Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine

D. Lauffenburger, D. Douek, G. Alter, 2023, JCI insight.

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial

C. Huon, S. Draper, C. Nielsen, 2024, NPJ vaccines.